secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001193125-26-158030
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa settles patent disputes with Intas; Endoxifen patents remain enforceable
-------------------------------------------------------------------------------

- Entered Settlement Agreement on April 13, 2026 with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve Endoxifen patent disputes.
- PTAB proceedings will be terminated; U.S. Patent Nos. 11,261,151 and 12,071,391 remain issued and enforceable.
- Mutual covenants prevent parties from challenging each other's specified Endoxifen patents and applications.
- Agreement preserves Atossa's ability to develop and commercialize Z-endoxifen base in oncology, endocrine disorders, and muscular dystrophy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526158030/0001193125-26-158030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526158030/d107774d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-158030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer